The Latest Analyst Ratings for Integra Lifesciences
Portfolio Pulse from Benzinga Insights
In the last quarter, Integra Lifesciences (NASDAQ:IART) received a mix of analyst ratings, with 1 bullish, 2 somewhat bullish, 4 indifferent, 1 somewhat bearish, and 1 bearish. The average price target is $52.0, indicating an upside from the current price of $41.3. However, this average has decreased by 12.78% from the previous average price target of $59.62.
July 12, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Integra Lifesciences received mixed analyst ratings in the last quarter, with an average price target of $52.0, indicating potential upside.
The mixed analyst ratings indicate uncertainty about the company's performance. While the average price target suggests potential upside, the decrease in the average price target from the previous quarter could be a cause for concern.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100